Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
07 August 2014Website:
http://www.t2biosystems.comNext earnings report:
07 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 01 Jul 2024 23:59:43 GMTDividend
Analysts recommendations
Institutional Ownership
TTOO Latest News
Shares of T2 Biosystems (NASDAQ: TTOO ) stock are rising higher after the medical diagnostics company disclosed that the Nasdaq Hearings Panel had provided it with an extension to regain compliance. T2 will have until May 20 to maintain a closing market capitalization of at least $35 million for at least 10 consecutive trading days.
T2 Biosystems Inc. (TTOO), a prominent player in the field of medical diagnostics, recently announced its financial results for the fourth quarter of 2023, signaling a pivotal moment for the company.
T2 Biosystems, Inc. (TTOO) Q4 2023 Earnings Call Transcript
Shares of T2 Biosystems (NASDAQ: TTOO ) are jumping higher by more than 30%. This comes as the diagnostics company announced that it had received U.S. Food and Drug Administration (FDA) 510(k) clearance for Acinetobacter baumannii (A.
LEXINGTON, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the fourth quarter and full year 2023 and business updates after market close on Thursday, February 15, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
T2 Biosystems (NASDAQ: TTOO) stock price has collapsed to a record low as concerns about the company's future continued. Shares of the popular penny stock have collapsed to a split-adjusted low of $4.72, meaning they have plunged by over 92% this year.
T2 Biosystems (NASDAQ: TTOO ) stock is in the green after the medical diagnostics company announced that it had received written notice from the Nasdaq Listing Qualifications Staff on Oct. 31 that it had regained compliance with Nasdaq's minimum bid requirement of $1. T2 had previously enacted a 1-for-100 reverse stock split that became effective as of Oct. 12 in order to lift TTOO stock above $1.
T2 Biosystems (NASDAQ: TTOO ) stock is plummeting lower following the company's announcement of a 1-for-100 reverse stock split and its preliminary third-quarter earnings. The reverse split was effective as of yesterday, with shares of TTOO beginning trading on a reverse split-adjusted basis as of this morning.
T2 Biosystems makes medical diagnostic testing equipment. The company reported a likely 60% in revenue in a preliminary third-quarter earnings report.
T2 Biosystems, Inc. (NASDAQ:TTOO ) Preliminary Q3 2023 Earnings Call Transcript October 12, 2023 4:30 PM ET Company Participants Trip Taylor - IR John Sperzel - Chairman & CEO Conference Call Participants Kyle Mikson - Canaccord Ben Haynor - Alliance Global Partners Operator Greetings. Welcome to T2 Biosystems Preliminary Third Quarter 2023 Financial Results and Business Update Call.
What type of business is T2 Biosystems?
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
What sector is T2 Biosystems in?
T2 Biosystems is in the Healthcare sector
What industry is T2 Biosystems in?
T2 Biosystems is in the Diagnostics & Research industry
What country is T2 Biosystems from?
T2 Biosystems is headquartered in United States
When did T2 Biosystems go public?
T2 Biosystems initial public offering (IPO) was on 07 August 2014
What is T2 Biosystems website?
https://www.t2biosystems.com
Is T2 Biosystems in the S&P 500?
No, T2 Biosystems is not included in the S&P 500 index
Is T2 Biosystems in the NASDAQ 100?
No, T2 Biosystems is not included in the NASDAQ 100 index
Is T2 Biosystems in the Dow Jones?
No, T2 Biosystems is not included in the Dow Jones index
When does T2 Biosystems report earnings?
The next expected earnings date for T2 Biosystems is 07 August 2024